Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Pulse and Peg Interferon Alpha 2b Therapy in HBeAg-positive Patients With Normal ALT
NCT02454764Withdrawn
- Sponsor
- Institute of Liver and Biliary Sciences
- Primary completion
- Jan 2018
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Sustained HBeAg seroconversion to anti-Hbe at 65 weeks. Status: withdrawn.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02454764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454764.